Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report

BACKGROUND: The development of anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) has remarkably improved the prognosis of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Alectinib, the second-generation ALK-TKI, has been approved as first-line treatment for a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lu-Ming, Zhao, Peng, Sun, Xu-Qi, Yan, Feng, Guo, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445061/
https://www.ncbi.nlm.nih.gov/pubmed/37621597
http://dx.doi.org/10.12998/wjcc.v11.i22.5322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445061/
https://www.ncbi.nlm.nih.gov/pubmed/37621597
http://dx.doi.org/10.12998/wjcc.v11.i22.5322

Ejemplares similares